Genexine Inc. | Ownership
Companies that own Genexine Inc.
The Vanguard Group, Inc.
294,270
1.44%
64
0%
07/31/2018
BlackRock Fund Advisors
145,139
0.71%
0
0%
09/05/2018
Baillie Gifford & Co.
93,356
0.46%
0
0.01%
04/30/2018
Norges Bank Investment Management
45,766
0.22%
-43,870
0%
12/31/2017
BlackRock Advisors (UK) Ltd.
32,694
0.16%
0
0%
09/05/2018
Mirae Asset Global Investments Co., Ltd.
31,292
0.15%
7,982
0.02%
04/30/2018
RAM Active Investments SA
17,128
0.08%
17,128
0.04%
06/30/2017
Charles Schwab Investment Management, Inc.
14,988
0.07%
0
0%
09/06/2018
SSgA Funds Management, Inc.
8,320
0.04%
0
0%
09/06/2018
TIAA-CREF Investment Management LLC
6,953
0.03%
0
0%
03/31/2018
| Address |
4/F, Korea Bio Park Bldg. B
Seongnam-si GY 13488
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.genexine.com |
| Updated |
09/14/2018 |
| Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam, South Korea. |
